Aptevo TherapeuticsFRA:AP82 29 EV-to-FCF is 0.18 as of Jul. 02, 2026. GuruFocus rates FRA:AP82 with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 333 Biotechnology companies, Aptevo Therapeutics ranks better than 93.09% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Aptevo Therapeutics's Enterprise Value is €-4.08 Mil.
Aptevo Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-23.21 Mil. Therefore, Aptevo Therapeutics's EV-to-FCF for today is 0.18.
The historical rank and industry rank for Aptevo Therapeutics's EV-to-FCF or its related term are showing as below:
FRA:AP82'
s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.17
Current: 0.17
During the past 13 years, the highest EV-to-FCF of Aptevo Therapeutics was 0.17. The lowest was 0.00. And the median was 0.00.
FRA:AP82's EV-to-FCF is ranked better than 93.09% of 333
companies
in the Biotechnology industry
Industry Median: 15.57
vs FRA:AP82: 0.17
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Aptevo Therapeutics's PE Ratio (TTM) for today is calculated as:
Aptevo Therapeutics's share price for today is €65970.00.
Aptevo Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-175.882.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Aptevo Therapeutics EV-to-FCF Related Terms
Aptevo Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Aptevo Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AP82 vs ENVB, ADIL, CNSP: EV-to-FCF Comparison
For the Biotechnology subindustry, Aptevo Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aptevo Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aptevo Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Aptevo Therapeutics's EV-to-FCF falls into.
Aptevo Therapeutics's current Enterprise Value is €-4.08 Mil.
Aptevo Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-23.21 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aptevo Therapeutics (FRA:AP82) has a EV-to-FCF of 0.18 as of Jul. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Aptevo Therapeutics and its competitors. According to the industry distribution chart, Aptevo Therapeutics ranks #23 out of 333 companies in the Biotechnology industry, placing it in the top 6.9%.
Is Aptevo Therapeutics' EV-to-FCF too high?
Aptevo Therapeutics' current EV-to-FCF is 0.18. The Biotechnology industry median EV-to-FCF is 15.57. Aptevo Therapeutics' value of 0.18 is 98.8% below this industry median. Based on the distribution chart, Aptevo Therapeutics ranks #23 out of 333 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Aptevo Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Aptevo Therapeutics' EV-to-FCF compare to ENVB and ADIL?
According to the Biotechnology industry distribution chart, Aptevo Therapeutics ranks #23 out of 333 companies for EV-to-FCF. This places Aptevo Therapeutics in the top 7% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 15.57. Aptevo Therapeutics' value of 0.18 is 98.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.57, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aptevo Therapeutics's current EV-to-FCF of 0.18 is 98.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Aptevo Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aptevo Therapeutics's current EV-to-FCF is 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptevo Therapeutics stock overvalued right now?
Aptevo Therapeutics (FRA:AP82) has a current EV-to-FCF of 0.18. The current EV-to-FCF is 0.18 and 98.8% below the Biotechnology industry median of 15.57. Aptevo Therapeutics' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Aptevo Therapeutics (FRA:AP82), the current EV-to-FCF is 0.18 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
29GF Score
Get the complete analysis for FRA:AP82
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AP82 has been successfully added to your 
